Clinical Trials
25 trialsNCT01804686 2026-06-05
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05421663 2026-06-05
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT03960840 2026-06-04
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Phase 1/2 Active not recruiting
NCT05139017 2026-06-04
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT07226843 2026-06-04
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Eli Lilly and Company
Phase 1 Recruiting
NCT05006716 2026-06-03
CaDAnCe-101
BeOne Medicines
Phase 1/2 Recruiting
NCT07200375 2026-06-03
GlofitReal
Hoffmann-La Roche
Recruiting
NCT04542824 2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2 Active not recruiting
NCT04663347 2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2 Active not recruiting
NCT05283720 2026-06-02
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT05660967 2026-06-02
EPCORE DLBCL-3
Genmab
Phase 2 Active not recruiting
NCT05952024 2026-06-02
ACRUE
AstraZeneca
Phase 2 Recruiting
NCT06500273 2026-06-02
ALPHA3
Allogene Therapeutics
Phase 2 Recruiting
NCT06395103 2026-06-01
MK-9999-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06717347 2026-05-29
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06890884 2026-05-29
MK-2140-011
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05144841 2026-05-28
MK-2140-004
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05826535 2026-05-28
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
Phase 1/2 Recruiting
NCT07609862 2026-05-27
A Phase Ib/II Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1/2 Not yet recruiting
NCT06806033 2026-05-26
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 2 Recruiting
NCT04628494 2026-05-22
EPCORE DLBCL-1
Genmab
Phase 3 Active not recruiting
NCT04824794 2026-05-19
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Phase 1/2 Terminated
NCT04661007 2026-05-18
J-MIND
Incyte Corporation
Phase 1/2 Active not recruiting
NCT06091865 2026-05-15
OLYMPIA-3
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT07519772 2026-05-15
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting